Abstract. Although existing guidelines recommend long-term follow-up of childhood cancer survivors (CCSs), their fertility has not been fully investigated in Japan. To address this issue, we organized a working panel consisting of medical specialists in foundation hospitals. We conducted questionnaire surveys targeting pediatric endocrinologists regarding reproduction in pediatric and adolescent cancer patients in collaboration with the CCS committee of the Japanese Society for Pediatric Endocrinology (JSPE). The first questionnaire was sent to 178 directors or councilors of the JSPE, and the second was sent to those who had provided answers on their experience with childbirth or fertility preservation. A total of 151 responses (84.8%) were obtained in the first survey. In the second survey, the response rate was 100% (39 respondents). There were 27 answers describing experiences with childbirth (16 from partners of male CCSs, 22 from female CCSs). A few cases of premature birth and low birth weight were reported. There were 25 answers describing experiences with fertility preservation; 21 were from male and 17 from female CCSs. It was mainly physicians who recommended fertility preservation. This nationwide questionnaire survey revealed that a limited number of Japanese pediatric endocrinologists had experience with childbirth and fertility preservation in CCSs. A further long-term follow-up study of their fertility is needed.
Introduction
The incidence of childhood cancer is estimated as 2,000 to 2,500 cases per year in Japan. Because of improvements in the treatment and prognosis of cancer, the number of childhood and adolescent cancer survivors has increased (1) . A significant proportion of survivors experience chronic health problems that result from cancer, its treatment, or both (2) (3) (4) . The Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, issued by the Children's Oncology Group, are recognized resources for healthcare professionals who provide ongoing care to survivors of pediatric malignancies (5) . Endocrine disorders are major problems that can occur after the cancer treatment is over (6, 7) . Thus, the Japanese Society for Pediatric Endocrinology (JSPE) issued a follow-up guide in 2011, with a minor revision in 2016, regarding childhood cancer survivor (CCS) care with the aim of ensuring all physicians involved in clinical practice undertake medical examinations for endocrine disorders (8) . Chemotherapy, radiation therapy, and surgery may damage gonadal function in patients with malignant and nonmalignant diseases (9) (10) (11) (12) . In 2013, the American Society of Clinical Oncology (ASCO) revised its guidelines for healthcare providers regarding fertility preservation in adults and children with cancer (13) . Even though gonadal dysfunction, subfertility, and premature ovarian insufficiency (POI) have been recognized as important late effects in CCSs (14), few surveys on this topic have been conducted in Japan (15) (16) (17) (18) . Most CCSs in Japan do not receive outpatient followup care as adults, resulting in no data on their long-term prognosis. Therefore, we conducted a survey to reveal the current clinical practice among pediatric endocrinologists in order to investigate issues and unmet needs associated with gonadal function or fertility in CCSs (19) . We subsequently conducted a second questionnaire survey to elucidate issues regarding childbirth and fertility preservation in CCSs; this survey Vol.26 / No.2 was based on the practical experience of Japanese pediatric endocrinologists.
Subjects and Methods
The first questionnaire was sent to 178 directors or councilors who are members of the JSPE (19) . The questionnaire consisted of 36 closed-ended questions regarding the professional background of the respondents, their experience with the follow-up of pediatric cancer patients, their opinions regarding gonadal function or fertility in these patients, the current status of their clinical practice, and a free-entry field to describe what measures they believe should be taken in the future to maintain gonadal function or preserve fertility in pediatric cancer patients.
The second survey was sent to 39 directors or councilors of the JSPE who had experience with childbirth in CCSs or fertility preservation, based on their answers to the previous survey. The questionnaire consisted of 2 main questions. Question 1 targeted respondents who had indicated experience with childbirth in CCSs (or their partners if male). Information regarding the number of such births, the associated hospitals, the health issues in the offspring of CCSs (for men), and the health issues in offspring, as well as the course of pregnancy/childbirth (for women) was collected. Question 2 was used for respondents who indicated experience with fertility preservation in childhood and adolescent cancer patients. The respondents were asked to provide data on the number of each preservation treatment method experienced, the associated hospitals, and the persons who suggested the treatment. Finally, respondents were given an opportunity to write free-response comments about issues or impressions. These self-reporting questionnaires were sent by mail along with an addressed return envelope. The survey period lasted from October 2015 to December 2015.
This study was approved by the ethical review board at Osaka University Hospital (approval No. 15203). The work was conducted 
Results

Questionnaire responses
The first questionnaire was sent to 178 (139 male and 39 female) directors or councilors of the JSPE. A total of 151 valid responses were obtained, giving a response rate of 84.8%. The second questionnaire was sent to 39 respondents who had indicated experience of childbirth or fertility preservation in CCSs in the first survey. We received 35 responses received from the 39 subjects who were sent the second survey. However, in some cases, several or all respondents from the same hospital submitted their answers collectively. Thus, the response rate was 100%. Therefore, the statistics below are given not as the number of respondents or the number of hospitals, but as the number of answers.
Childbirth in CCSs
Sixteen of the 35 (45.7%) answers indicated experience of childbirth in partners of male CCSs ( Table 1 ). The numbers of births experienced up to now were 1 (n = 8), 2 (n = 5), 3 (n = 1), 18 (n = 1), and unknown (n = 1). The experience was acquired at the respondent's current hospital (n = 8), at another hospital (n = 7), or both (n = 1).
Twenty-two of the 35 (62.9%) answers indicated experience of childbirth in female CCSs ( Table 2 ). The numbers of births experienced so far were 1 (n = 6), 2 (n = 6), 3 (n = 3), 4 (n = 3), 5 (n = 2), 8 (n = 1), and 21 (n = 1). The experience was gained at the respondent's current hospital April 2017 (n = 13), at another hospital (n = 6), or both (n = 3). We eliminated any overlapping answers and consolidated them. Experience was gained in 21 hospitals, of which 6 were major pediatric cancer hospitals and 1 was a core pediatric cancer hospital.
Health issues in pregnancy and childbirth in CCSs
Of the 16 answers indicating experience with childbirth in partners of male CCSs, 10 reported no health issues, none reported health issues, and 6 indicated that the responders did not know. Of the 22 answers indicating experience of childbirth in female CCSs, 14 reported no health issues, 3 reported health issues in the child alone, 1 reported health issues in the mother alone (significant hemorrhage due to postpartum placental retention), 1 reported health issues in both the mother and child (threatened premature labor, low birth weight, and respiratory distress syndrome), and 3 indicated that they did not know if there were any health issues. Specific health issues were described in the free-style comments for 8 answers. Six premature births were reported, and these occurred in mothers who had received stem cell transplantation (n = 4) and/or abdominal radiation (n = 4). There was 1 neonatal death, 1 spontaneous abortion, and 1 child with a cleft palate; however, there was no major fetal malformation.
Fertility preservation in male CCSs
Twenty-one of 35 (60.0%) answers indicated experience of fertility preservation in male CCSs. The numbers of patients experiencing fertility preservation based on these positive answers are detailed in Table 3 . Sixteen answers indicated experience with sperm cryopreservation, and the numbers of patients detailed in these positive answers were 1 (n = 7), 2 (n = 4), 3 (n = 2), 5 (n = 1), and 'unknown' (n = 2). Two answers also indicated experience with testicular tissue cryopreservation, but these answers referred to the same patient. Ten answers indicated experience with gonadal (testicular) shielding before radiotherapy, and the numbers of patients described in these positive answers were 1 (n = 2), 2 (n = 1), 5 (n = 2), multiple (n = 3), and unknown (n = 2). There were no answers indicating other forms of male CCS fertility preservation.
Fertility preservation in female CCS
Seventeen of 35 (48.6%) answers indicated experience with fertility preservation in female CCSs. The patient numbers experiencing fertility preservation according to these positive answers are detailed in Table 4 . Three answers indicated experience with oocyte cryopreservation, and the numbers of patients given in these positive answers were 1 (n = 2) and 2 (n = 1). Four answers indicated experience with ovarian cryopreservation, and the numbers of patients detailed these positive answers were 1 (n = 2), 3 (n = 1), and 10-15 (n = 1). Nine answers indicated experience with gonadal (ovarian) shielding before radiotherapy, and the numbers of patients described in these positive answers were 1 (n = 2), 2 (n = 1), 4 (n = 1), 6 (n = 1), multiple (n = 2), and unknown (n = 2). Four answers indicated experience with ovarian transposition before radiotherapy, and the numbers of patients seen for undergoing this procedure were 1 (n = 1), 2 (n = 2), and multiple (n = 1). Seven answers indicated experience with gonadal suppression with a luteinizing hormone releasing hormone analog, and the numbers of patients detailed in these positive answers were 1 (n = 3), 2 (n = 2), 20 (n = 1), and multiple (n = 1). There were no answers indicating other forms of female CCS fertility preservation.
Person who proposed fertility preservation
Of the 25 answers indicating experience with fertility preservation in male and/or female CCSs, fertility preservation was proposed by the medical care provider (n = 21), the patient (n = 1), the patient's guardian (n = 1), or was unknown (n = 4) [multiple answers were accepted].
Details of childbirth and issues regarding fertility preservation
Twenty-seven (77.1%) answers included information detailed as free-response comments. Because of the retrospective nature of this study, it is difficult to be sure of the cause; however, health issues were reported both in the mother (at birth) and in her children. Both premature birth and low birth weight were speculated to be caused by the radiation to the uterus in childhood. Various difficulties and problems with fertility preservation were reported. Although rare, unexpected childbirths were reported at 6 hospitals as a result of natural conception in women receiving estrogen replacement therapy (Kauffman therapy) for POI caused by cancer treatment.
Discussion
This questionnaire survey revealed that a limited number of Japanese pediatric endocrinologists have experience with childbirth and fertility preservation in childhood and adolescent cancer patients. The second questionnaire was sent to the respondents of the previous survey who had indicated experience with childbirth (or childbirth in partners for men) or fertility preservation. Although the sample size for the secondary survey was small (n = 39), its reliability is strengthened by the high rate of responses (151 out of 178: 84.8%) from the previous nationwide study supported by the JSPE (19) . There were 35 responses to the secondary survey, which equates to a 100% response rate when taking into account respondents from the same institution collating their responses. This excellent response rate indicates a high awareness of the importance of these issues among Japanese pediatric endocrinologists. In addition, it is noteworthy that many responses were obtained from collaborations between pediatric endocrinologists and pediatric oncologists working at the same hospitals.
Twenty-seven of the 35 (77.1%) answers indicated experience with childbirth in CCSs. One physician working at the cancer center reported experience including young adult patients; therefore, the number of births was much larger than that reported by others. A smaller number of answers were obtained about childbirth in partners of male CCSs than in female CCSs. It is unlikely that this is because of a lower rate of childbirth among the partners of male CCSs; rather, it indicates that less information was obtained about childbirth among the partners of male CCSs, or that there were a greater number of male CCSs who were lost to follow-up prior to the birth of their child. For example, 6 out of 16 answers (37.5%) about health issues in children born to male CCSs were unknown. One freeresponse comment was, "I do not think there are any health issues, but I have not specifically asked on them". In contrast, more information was collected about childbirth among female CCSs because the patient herself experiences pregnancy and birth. The number of unknown responses among female CCSs (n = 3, 13.6%) was lower than that of male CCSs. It is unclear whether these CCSs were adequately followed-up during pregnancy. A few cases of premature birth and low birth weight were reported. It has been reported that CCSs do not have an increased risk of congenital anomalies (20, 21) , although female CCSs have a higher risk of premature birth and a low birth weight after radiation exposure to the uterus (22) (23) (24) (25) . It is not known how many of the pregnancies described in this survey were facilitated by assisted reproductive technology; further research is required to elucidate the degree of infertility in CCSs.
Notably, multiple responses described pregnancy in CCSs undergoing estrogen replacement therapy. Pediatric endocrinologists usually explain to these patients that POI makes conceiving almost impossible; however, these results demonstrate that this may not be the case. Further surveys on this issue may improve medical care for female cancer survivors.
The most common form of fertility preservation described was sperm cryopreservation. This is a relatively simple, long-established, and non-invasive procedure in which adult men provide semen samples for cryopreservation. However, as described in a free-response comment, collecting sperm from young patients is problematic and may involve significant embarrassment and other forms of psychological impact. Even if sperm collection was possible, cryopreservation expenses may have become a burden for a prolonged period until patients desired children. The young age of patients is a key factor affecting these issues for both sexes, and healthcare providers must be aware of the potential physical, psychological, and economic burdens. Many other issues are also highlighted in the surveys. In terms of the healthcare system, the quality varies among hospitals and can be affected by a lack of specialists in the same hospital, medical expenses, doctors' transfer, movement of young people from rural to urban areas, and the difficulty of collecting historical information. In terms of the treatment itself, issues include different treatment regimens, differences in diseases, a lack of information provided to the patients, and cessation or completion of followup.
In almost all cases, it was a doctor who proposed fertility preservation. Faced with imminent cancer treatment, both children and their guardians are hard-pressed to consider fertility preservation treatment. Compared with Western countries, discussion of fertility issues is insufficient in Japan (26) . To increase such opportunities for patients, the ASCO guidelines revised in 2013 and oncofertility, an important collaboration between reproductive medicine and oncology, should be widely understood (13, 27) . To this end, we are aiming to perform various Vol.26 / No.2 trials and research, construct medical networks, offer information using booklets and the internet, open consulting services for oncofertility, and educate both healthcare providers and cancer patients (26, 28, 29) .
There are some limitations in this questionnaire survey. The sample size is small, and we could not gather information from institutions that did not have a pediatric endocrinologist. Similar long-term follow-up studies on a larger scale should be performed from the viewpoints of specialized pediatric oncologists, gynecologists, and urologists. A prospective nationwide collaborative study is anticipated in Japan.
